Qiagen N.V. Company Profile
NYSE: QGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Pre-market: 44.84 +0.68%
Qiagen N.V. at a glance
Qiagen N.V. (NYSE: QGEN) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Venlo, Netherlands. Qiagen N.V. is led by Mr. Jonathan M. Pratt and employs about 5,500 people. The company's shares have traded publicly since 2026.
At a market capitalization of $9.23 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001015820, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Qiagen N.V. do?
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Business description based on the company's public filings.
Company information
- Legal name
- Qiagen N.V.
- Ticker
- NYSE: QGEN
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Jonathan M. Pratt
- Employees
- 5,500
- Headquarters
- Hulsterweg 82, Venlo, Netherlands
- Phone
- 31 77 355 6600
- Website
- qiagen.com
- IPO year
- 2026
- Market cap
- $9.23B
- SEC CIK
- 0001015820
Companies similar to Qiagen N.V.
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KYMRKymera Therapeutics Inc. | 109.30 | +0.88% | $8.99B | vs QGEN |
| PCVXVaxcyte Inc. | 65.02 | -2.90% | $9.67B | vs QGEN |
| KRYSKrystal Biotech Inc. | 327.30 | +0.84% | $9.69B | vs QGEN |
| TWSTTwist Bioscience Corporation | 152.05 | -2.31% | $10.08B | vs QGEN |
| RGENRepligen Corporation | 163.84 | -2.02% | $10.40B | vs QGEN |
| IBRXImmunityBio Inc. | 9.91 | +1.64% | $10.50B | vs QGEN |
| TECHBio-Techne Corp | 72.45 | -0.11% | $11.36B | vs QGEN |
| IMVTImmunovant Inc. | 30.26 | -5.56% | $6.25B | vs QGEN |